|
Gene: WWP1 |
Gene summary for WWP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | WWP1 | Gene ID | 11059 |
Gene name | WW domain containing E3 ubiquitin protein ligase 1 | |
Gene Alias | AIP5 | |
Cytomap | 8q21.3 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q9H0M0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11059 | WWP1 | GSM4909290 | Human | Breast | IDC | 3.28e-07 | 3.90e-01 | 0.2096 |
11059 | WWP1 | GSM4909293 | Human | Breast | IDC | 8.15e-05 | 2.41e-01 | 0.1581 |
11059 | WWP1 | GSM4909297 | Human | Breast | IDC | 1.00e-02 | 3.07e-01 | 0.1517 |
11059 | WWP1 | GSM4909298 | Human | Breast | IDC | 2.71e-12 | 3.68e-01 | 0.1551 |
11059 | WWP1 | GSM4909304 | Human | Breast | IDC | 2.88e-28 | 6.35e-01 | 0.1636 |
11059 | WWP1 | GSM4909306 | Human | Breast | IDC | 1.46e-17 | 4.85e-01 | 0.1564 |
11059 | WWP1 | GSM4909308 | Human | Breast | IDC | 1.48e-03 | 2.17e-01 | 0.158 |
11059 | WWP1 | GSM4909311 | Human | Breast | IDC | 1.20e-05 | 1.71e-02 | 0.1534 |
11059 | WWP1 | GSM4909317 | Human | Breast | IDC | 3.73e-07 | 3.59e-01 | 0.1355 |
11059 | WWP1 | GSM4909319 | Human | Breast | IDC | 1.01e-06 | -1.41e-02 | 0.1563 |
11059 | WWP1 | M1 | Human | Breast | IDC | 3.13e-10 | 4.91e-01 | 0.1577 |
11059 | WWP1 | NCCBC2 | Human | Breast | DCIS | 7.94e-05 | 6.14e-01 | 0.1554 |
11059 | WWP1 | DCIS2 | Human | Breast | DCIS | 1.06e-37 | 1.77e-01 | 0.0085 |
11059 | WWP1 | CCI_2 | Human | Cervix | CC | 6.20e-09 | 1.17e+00 | 0.5249 |
11059 | WWP1 | CCI_3 | Human | Cervix | CC | 4.72e-08 | 7.21e-01 | 0.516 |
11059 | WWP1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.43e-20 | -4.41e-01 | 0.0155 |
11059 | WWP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.76e-07 | -4.80e-01 | -0.1808 |
11059 | WWP1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.17e-07 | -6.02e-01 | -0.1207 |
11059 | WWP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.05e-04 | -3.67e-01 | -0.1526 |
11059 | WWP1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.66e-07 | -4.31e-01 | -0.1464 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
GO:001905814 | Breast | IDC | viral life cycle | 61/1434 | 317/18723 | 1.61e-11 | 2.77e-09 | 61 |
GO:001049814 | Breast | IDC | proteasomal protein catabolic process | 75/1434 | 490/18723 | 5.59e-09 | 4.41e-07 | 75 |
GO:004440314 | Breast | IDC | biological process involved in symbiotic interaction | 52/1434 | 290/18723 | 6.55e-09 | 5.03e-07 | 52 |
GO:004217614 | Breast | IDC | regulation of protein catabolic process | 63/1434 | 391/18723 | 1.32e-08 | 9.61e-07 | 63 |
GO:005212614 | Breast | IDC | movement in host environment | 32/1434 | 175/18723 | 3.33e-06 | 1.22e-04 | 32 |
GO:005170114 | Breast | IDC | biological process involved in interaction with host | 35/1434 | 203/18723 | 4.72e-06 | 1.63e-04 | 35 |
GO:004316114 | Breast | IDC | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1434 | 412/18723 | 9.55e-06 | 2.68e-04 | 57 |
GO:004440914 | Breast | IDC | entry into host | 28/1434 | 151/18723 | 1.02e-05 | 2.82e-04 | 28 |
GO:004671814 | Breast | IDC | viral entry into host cell | 27/1434 | 144/18723 | 1.18e-05 | 3.14e-04 | 27 |
GO:004573214 | Breast | IDC | positive regulation of protein catabolic process | 37/1434 | 231/18723 | 1.46e-05 | 3.71e-04 | 37 |
GO:000989614 | Breast | IDC | positive regulation of catabolic process | 62/1434 | 492/18723 | 7.06e-05 | 1.42e-03 | 62 |
GO:001603224 | Breast | DCIS | viral process | 73/1390 | 415/18723 | 3.40e-12 | 6.88e-10 | 73 |
GO:001905824 | Breast | DCIS | viral life cycle | 59/1390 | 317/18723 | 4.05e-11 | 5.74e-09 | 59 |
GO:001049824 | Breast | DCIS | proteasomal protein catabolic process | 75/1390 | 490/18723 | 1.44e-09 | 1.40e-07 | 75 |
GO:004217624 | Breast | DCIS | regulation of protein catabolic process | 62/1390 | 391/18723 | 9.98e-09 | 7.53e-07 | 62 |
GO:004440323 | Breast | DCIS | biological process involved in symbiotic interaction | 49/1390 | 290/18723 | 4.70e-08 | 2.89e-06 | 49 |
GO:004316124 | Breast | DCIS | proteasome-mediated ubiquitin-dependent protein catabolic process | 57/1390 | 412/18723 | 3.76e-06 | 1.16e-04 | 57 |
GO:005212624 | Breast | DCIS | movement in host environment | 31/1390 | 175/18723 | 4.93e-06 | 1.45e-04 | 31 |
GO:005170124 | Breast | DCIS | biological process involved in interaction with host | 34/1390 | 203/18723 | 6.30e-06 | 1.78e-04 | 34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414416 | Breast | DCIS | Endocytosis | 37/846 | 251/8465 | 9.92e-03 | 4.40e-02 | 3.24e-02 | 37 |
hsa0414417 | Breast | DCIS | Endocytosis | 37/846 | 251/8465 | 9.92e-03 | 4.40e-02 | 3.24e-02 | 37 |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041446 | Colorectum | FAP | Endocytosis | 78/1404 | 251/8465 | 6.20e-09 | 2.96e-07 | 1.80e-07 | 78 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WWP1 | SNV | Missense_Mutation | c.163N>C | p.Lys55Gln | p.K55Q | Q9H0M0 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
WWP1 | SNV | Missense_Mutation | c.979N>A | p.Ala327Thr | p.A327T | Q9H0M0 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
WWP1 | SNV | Missense_Mutation | c.2548N>C | p.Val850Leu | p.V850L | Q9H0M0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CD-A487-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | epirubicin | CR | |
WWP1 | SNV | Missense_Mutation | rs767773883 | c.152N>T | p.Thr51Met | p.T51M | Q9H0M0 | protein_coding | deleterious(0) | possibly_damaging(0.501) | TCGA-CG-4442-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
WWP1 | SNV | Missense_Mutation | c.1875N>A | p.Asn625Lys | p.N625K | Q9H0M0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EQ-A4SO-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
WWP1 | SNV | Missense_Mutation | c.1996A>G | p.Met666Val | p.M666V | Q9H0M0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-HU-A4HD-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
WWP1 | SNV | Missense_Mutation | novel | c.1756N>A | p.Ala586Thr | p.A586T | Q9H0M0 | protein_coding | tolerated(0.25) | benign(0.142) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
WWP1 | SNV | Missense_Mutation | novel | c.2666N>T | p.Thr889Ile | p.T889I | Q9H0M0 | protein_coding | deleterious(0) | possibly_damaging(0.503) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
WWP1 | SNV | Missense_Mutation | novel | c.838G>T | p.Asp280Tyr | p.D280Y | Q9H0M0 | protein_coding | deleterious(0.04) | benign(0.322) | TCGA-VQ-A8PP-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |